600380.SH
健康元
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 9.35
−5.36%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 14.8B | 15.2B | 15.6B | 16.6B | 17.1B |
| Cost of Revenue | 5.5B | 5.7B | 5.8B | 6.3B | 6.3B |
| Gross Profit | 9.3B | 9.5B | 9.8B | 10.3B | 10.9B |
| Operating Expenses | |||||
| R&D Expense | 1.2B | 1.3B | 1.4B | 1.7B | 1.7B |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 851.8M | 870.5M | 911.6M | 930.5M | 992.5M |
| Selling & Marketing Expense | 4.1B | 4.1B | 3.9B | 4.4B | 5.0B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 6.1B | 6.2B | 6.2B | 6.8B | 7.5B |
| Cost and Expenses | 11.6B | 11.9B | 12.0B | 13.1B | 13.8B |
| Operating Income (EBIT) | 3.4B | 3.5B | 3.6B | 3.5B | 3.5B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 3.3B | 3.4B | 3.6B | 3.5B | 3.5B |
| Income Tax Expense | 464.7M | 501.3M | 592.1M | 614.5M | 561.8M |
| Bottom Line | |||||
| Net Income | 1.3B | 1.3B | 1.4B | 1.4B | 1.5B |
| Earnings from Cont. Ops | 2.8B | 2.9B | 3.0B | 2.9B | 2.9B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 1.3B | 1.3B | 1.4B | 1.4B | 1.5B |
| Per Share | |||||
| Basic EPS | CN¥0.72 | CN¥0.73 | CN¥0.74 | CN¥0.76 | CN¥0.79 |
| Diluted EPS | CN¥0.72 | CN¥0.73 | CN¥0.74 | CN¥0.76 | CN¥0.79 |
| Revenue Per Share | CN¥8.23 | CN¥8.32 | CN¥8.34 | CN¥8.77 | CN¥9.05 |
| Shares | |||||
| Basic Shares Outstanding | 1.8B | 1.8B | 1.9B | 1.9B | 1.9B |
| Diluted Shares Outstanding | 1.8B | 1.8B | 1.9B | 1.9B | 1.9B |
| Profitability Metrics | |||||
| EBITDA | — | 4.3B | 4.5B | 4.6B | 4.3B |
| D&A | — | 874.2M | 871.1M | 1.1B | 863.4M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026